Cancer Pain

  • Samuel J. Hassenbusch

Abstract

Approximately four million people in the world die each year from cancer, which accounts for 10% to 20% of deaths from all causes.1 It is estimated that 50% to 60% of all patients with a terminal illness will have significant pain.2–4 Of these patients with pain, as many as 10% will have cancer pain that is considered intractable or refractory to medical management because of intolerable side effects with systemic medications and/or sedation causing significantly lowered mental status.5 The pain in these terminally ill patients is a direct result of the tumor in 65% to 75%, associated with or a result of the cancer therapy in 20% to 30% and unrelated to either in 5% to 10%.6,7 The etiology (ie, tumor, cancer therapy, or unrelated to either of these two causes) of the pain will greatly influence the choice and the efficacy of pain treatment options.

Keywords

Phenol Corticosteroid Morphine Oncol Stratification 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    World Health Organization. Cancer as a global problem. Weekly Epidemiol Records. 1984;59: 125–126.Google Scholar
  2. 2.
    Bonica JJ. Importance of the problem. In: Bonica JJ, Ventafridda V, eds. Advances in Pain Research and Therapy. New York: Raven Press; 1979;2.Google Scholar
  3. 3.
    Bonica JJ. Treatment of cancer pain: current status and future needs. In: Fields HL, ed. Advances in Pain Research and Therapy. New York: Raven Press, 1985;9:589–616.Google Scholar
  4. 4.
    Bonica JJ, Ventafridda V, Twycross RG. Cancer pain. In: Bonica JJ, ed. The Management of Pain. Philadelphia, Pa: Lea & Febiger; 1990;400–460.Google Scholar
  5. 5.
    Baines M, Kirkham SR. Cancer pain. In: Wall PD, Melzack R, eds. Textbook of Pain. New York: Churchill Livingstone; 1989;590–597.Google Scholar
  6. 6.
    Foley KM. Control of pain in cancer. In: Calabrisi P, Schein P, Rosenberg SA, eds. Medical Oncology: Basic Principles and Clinical Management of Cancer. New York: Macmillan; 1985;1385–1405.Google Scholar
  7. 7.
    Kanner RM, Foley KM. Patterns of narcotic drug use in a cancer pain clinic. Ann NY Acad Sci. 1981;362:161–172.PubMedCrossRefGoogle Scholar
  8. 8.
    Linton SJ, Götestam KG. A clinical comparison of two pain scales: correlation, remembering chronic pain, and a measure of compliance. Pain. 1983; 17:57–65.PubMedCrossRefGoogle Scholar
  9. 9.
    DeLaney TJ, Rowlinson JC, Carron H, et al. Epidural steroid effects on nerves and meninges. Anesth Analg. 1980;59:610–614.PubMedGoogle Scholar
  10. 10.
    Bonica JJ, ed. Clinical Applications of Diagnostic and Therapeutic Nerve Blocks. Springfield, Ill: Charles C. Thomas; 1959.Google Scholar
  11. 11.
    Bonica JJ. Management of pain with regional analgesia. Postgrad Med J. 1984;60:897–904.PubMedCrossRefGoogle Scholar
  12. 12.
    Shealy CN. Percutaneous radiofrequency denervation of spinal facets. Treatment for chronic back pain and sciatica. J Neurosurg. 1975;43:448–451.PubMedCrossRefGoogle Scholar
  13. 13.
    Lloyd JW, Barnard JD, Glynn CJ. Cryoanalgesia. A new approach to pain relief. Lancet. 1976; 2:932–934.PubMedCrossRefGoogle Scholar
  14. 14.
    Pagura JR. Percutaneous radiofrequency spinal rhizotomy. Appl Neurophysiol. 1983;46:138–146.PubMedGoogle Scholar
  15. 15.
    Drechsel U. Treatment of cancer pain with neurolytic agents. Recent Results Cancer Res. 1984; 89:137–147.PubMedCrossRefGoogle Scholar
  16. 16.
    Tasker RR. Percutaneous cordotomy: the lateral high cervical technique. In: Schmidek HH, Sweet WH, eds. Operative Neurosurgical Techniques. Indications, Methods, and Results. New York: Grune & Stratton; 1988;1191–1205.Google Scholar
  17. 17.
    Papo I. Spinal posterior rhizotomy and commissural myelotomy in the treatment of pain. In: Bonica JJ, Ventrafridda V, eds. Advances in Pain Research and Therapy. New York: Raven Press; 1979;2:439.Google Scholar
  18. 18.
    Schvarcz JR. Spinal cord stereotactic techniques re trigeminal nucleotomy and extralemniscal myelotomy. Appl Neurophysiol. 1978;41:99–112.PubMedGoogle Scholar
  19. 19.
    Mayanagi Y, Sano K, Suzuki I, et al. Stimulation and coagulation of the posteromedial hypothalamus for intractable pain, with reference to beta-endorphins. Appl Neurophysiol. 1982;45:136–142.PubMedGoogle Scholar
  20. 20.
    Hassenbusch SJ, Pillay PK, Barnett GH. Radiofrequency cingulotomy for intractable cancer pain using stereotaxis guided by magnetic resonance imaging. Neurosurgery. 1990;27:220–223.PubMedCrossRefGoogle Scholar
  21. 21.
    Laitinen LV. CT-guided ablative stereotaxis without ventriculography. Appl Neurophysiol. 1985;48:1821.Google Scholar
  22. 22.
    Hassenbusch SJ, Pillay PK, Magdinec M, et al. Constant infusion of morphine for intractable cancer pain using an implanted pump. J Neurosurg. 1990;73:405–409.PubMedCrossRefGoogle Scholar
  23. 23.
    North RB, Ewend MG, Lawton MT, et al. Failed back surgery syndrome: 5-year follow-up after spinal cord stimulator implantation. Neurosurgery. 1991;28:692–699.PubMedCrossRefGoogle Scholar
  24. 24.
    Tasker RR. Pain due to central nervous system pathology. In: Bonica JJ, ed. The Management of Pain. Philadelphia, Pa: Lea & Febiger; 1990:264–283.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Samuel J. Hassenbusch

There are no affiliations available

Personalised recommendations